Bavarian Nordic's RSV production takes a back seat to monkeypox shot: ”This is the responsibility we must shoulder"

As the world’s only drugmaker with a monkeypox vaccine, Bavarian Nordic has a moral obligation to produce as many doses as it can, says CFO Henrik Juuel. Consequently, the company’s RSV candidate production will be moved abroad.

Photo: Bavarian Nordic / PR

Bavarian Nordic has decided that its time for the commercial production of its RSV vaccines to move out of its factory located in its home country of Denmark.

The company’s chief financial officer, Henrik Juuel, says there simply isn’t enough production capacity at its factory in the Danish town of Kvistgård, 40 kilometers north of Copenhagen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Latest news

See all jobs